Ahmad Asad, Akhtar Juber, Ahmad Mohammad, Khan Mohammad Irfan, Singh Aditya, Islam Anas
Faculty of Pharmacy, Integral University, Lucknow, 226026, India.
Recent Adv Antiinfect Drug Discov. 2025;20(2):92-111. doi: 10.2174/0127724344318310241018113206.
Multidrug-resistant tuberculosis (MDR-TB) poses a persistent challenge to global health, necessitating continuous efforts to enhance treatment efficacy. Bedaquiline, a cornerstone in MDR-TB management, presents biopharmaceutical challenges that impact its therapeutic potential. This review provides a comprehensive analysis of recent innovations in drug delivery strategies designed to optimize Bedaquiline's efficacy and improve MDR-TB treatment outcomes. Through a systematic examination of various delivery systems, including nanotechnology and formulation advancements, we explore their potential in addressing drug solubility and bioavailability challenges. Emphasizing the integration of Quality by Design (QbD) principles, this review aims to present a cohesive overview of evolving Bedaquiline delivery innovations, providing valuable insights for researchers and healthcare practitioners working towards advancing MDR-TB treatment strategies.
耐多药结核病（MDR-TB）对全球卫生构成持续挑战，因此需要不断努力提高治疗效果。贝达喹啉是耐多药结核病管理的基石，但存在生物制药方面的挑战，影响其治疗潜力。本综述全面分析了旨在优化贝达喹啉疗效和改善耐多药结核病治疗结果的药物递送策略的最新创新。通过系统考察各种递送系统，包括纳米技术和制剂进展，我们探讨了它们在解决药物溶解度和生物利用度挑战方面的潜力。本综述强调设计质量（QbD）原则的整合，旨在对不断发展的贝达喹啉递送创新进行连贯概述，为致力于推进耐多药结核病治疗策略的研究人员和医疗从业者提供有价值的见解。
